<DOC>
	<DOCNO>NCT00186589</DOCNO>
	<brief_summary>To test new way approach hematopoietic stem cell transplantation Relapsed Resistant Non-Hodgkin 's Lymphoma .</brief_summary>
	<brief_title>90Y-IBRITUMOMAB Tiuxetan AHCI With HD Chemotherapy Autologous Transplantation Relapsed Resistant NHL</brief_title>
	<detailed_description>This single center phase I dose escalation trial single course IDEC-Y2B8 ( 90Y-ibritumomab tiuxetan , Zevalin ) autologous peripheral blood progenitor cell infusion follow high dose chemotherapy AHCT patient relapse refractory B-cell NHL . In step one , image dose IDEC-In2B8 ( 111In- ibritumomab tiuxetan , Zevalin ) follow one week later IDEC-Y2B ; precede infusion 250 mg/m2 rituximab . Imaging do immediately ( within 1 hr ) , 4 - 6 hour 1 , 3 , 6 day 90Y-ibritumomab tiuxetan .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion Criteria Step 1 4.1 Histologically proven , recurrent refractory , CD20+ Bcell NHL review SUMC . 4.11 The definition recurrent disease : previous partial response ( PR ) complete response ( CR ) treatment follow disease progression . 4.12 The definition refractory disease : failure achieve PR CR progression primary induction therapy subsequent salvage therapy . Patients respond treatment progress within 60 day also consider refractory . 4.13 CD20 expression may determine immunohistochemistry flow cytometry . Whenever possible , confirmation CD20+ status make current , active disease . 4.14 The definition NHL make SUMC pathologist use World Health Organization Classification Hematopoietic Lymphoid Tissues ( Appendix A ) . 4.15 The diagnosis make excisional biopsy whenever possible . Biopsy refractory recurrent disease prefer fine needle aspirate supportive morphology immunohistochemistry acceptable . Paraffin tissue tissue array study seek every patient . 4.2 Age 1870 year 4.21 Age base actual date birth . 4.22 Pediatric patient eligible study transplant separate dedicate unit protocol . 4.3 ECOG performance status 02 ( Appendix B ) 4.4 Computerized tomography scan chest , abdomen pelvis within 4 week registration . Assessment response last chemotherapy prior registration mandatory . 4.41 Response assess accord international consensus criterion ( Cheson et al . J Clin Oncol 17:1244 , 1999 ) 4.42 Standard definition chest , abdomen pelvis use radiographic study . 4.5 Gallium scan PET scan determination disease within 4 week registration highly recommend . 4.51 Gallium PET scan whole body scan 4.6 Bone marrow biopsy cytogenetic analysis within 8 week registration . Patients must &lt; 25 % involvement intratrabecular bone marrow cellularity NHL . 4.7 Adequate ( &gt; 4 x 10^6/kg CD34+ ) peripheral blood progenitor cell collect apheresis . 4.8 Women childbearing potential sexually active male strongly advise use accept effective method birth control . 4.9 No chemotherapy corticosteroid administer within 4 week initiation protocol therapy . 4.10 Pretreatment absolute neutrophil count &gt; 1000/mm^3 platelet count &gt; 150,000/ mm^3 . 4.11 Patients must pretreatment serum bilirubin &lt; 2 x institutional ULN , transaminases &lt; 2 x institutional ULN , serum creatinine &lt; 2 x institutional ULN measure estimate creatinine clearance &gt; 60 cc/min follow formula ( test must perform within 28 day prior registration ) : Estimated Creatinine Clearance = ( 140 age ) X WT ( kg ) X 0.85 female X creatinine ( mg/dl ) 4.12 Patients must EKG within 42 day prior registration show significant abnormality suggestive active cardiac disease . 4.13 Patients must radionuclide ejection fraction &gt; 45 % within 42 day registration . 4.14 Patients must correct diffusion capacity 70 % great . 4.15 Patients must inform investigational nature study must sign give write informed consent accordance institutional federal guideline . Inclusion Criteria Step 2 4.30 Absolute neutrophil count recovery &gt; 1000/mm^3 platelet recovery count &gt; 100,000/ mm^3 . 4.31 Corrected diffusing capacity &gt; 60 % . 4.32 Resting ejection fraction &gt; 45 % . 4.33 Serum bilirubin &lt; 2 , SGOT ( AST ) &lt; 2 x ULN , SGPT ( ALT ) &lt; 2 x ULN . Creatinine &lt; 2 x ULN measure estimate creatinine clearance &gt; 60 cc/min . Exclusion Criteria Step 1 4.16 Patients know allergy etoposide history Grade 3 hemorrhagic cystitis cyclophosphamide eligible . 4.17 No prior malignancy allow except adequately treat basal cell squamous cell skin cancer , situ cervical cancer cancer patient diseasefree five year . 4.18 Patients know human immunodeficiency virus ( HIV ) positive ineligible concern opportunistic infection hematologic reserve consider significantly great population . The antibody test HIV must perform within 42 day registration . 4.19 Patients require therapy coronary artery disease , cardiomyopathy , dysrhythmia , congestive heart failure eligible . 4.20 Pregnant breastfeed woman ineligible due know birth defect associate treatment use study . 4.21 Patients prior radiotherapy &gt; 25 % active marrow exclude . 4.22 Patients treat previously radioimmunotherapy exclude . 4.23 Patients pleural effusion ascites exclude . 4.24 Patients may receive prior rituximab within past 4 week . 4.25 Patients prior autologous transplantation ineligible . 4.26 Patients CNS disease ineligible . Exclusion Criteria Step 2 4.33 Drop diffuse capacity &gt; 25 % study entry . 4.34 Drop rest ejection fraction &gt; 20 % . 4.35 Failure recover peripheral blood count ( ANC &gt; 1000/mm^3 platelet recovery count &gt; 100,000/mm^3 within 4 week radioimmunotherapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>